Is Dr Lalchand. Lab overvalued or undervalued?

As of 19 September 2025, the valuation grade for Dr Lalchand Lab has moved from expensive to attractive, indicating a significant shift in its market perception. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 9.97, an EV to EBITDA of 10.33, and a Price to Book Value of 1.00, which are notably lower than many peers in the healthcare sector.
In comparison, Apollo Hospitals has a PE ratio of 71.29 and an EV to EBITDA of 36.65, while Max Healthcare is even higher at a PE of 93.83 and an EV to EBITDA of 58.13, highlighting the relative attractiveness of Dr Lalchand Lab. The company's recent stock performance has also shown resilience, with a year-to-date return of 36.15%, significantly outperforming the Sensex's 5.74% during the same period.